中信里昂上调鹰瞳科技（2251.HK）目标价至20.7港元，维持买入评级

权证网04-02

中信里昂发布研报称，受益于疫情后健康体检活动恢复检测次数增加和平均单价的提升，鹰瞳科技2023年度营收达到2.04亿元人民币，同比增长79.5%。毛利率同比增长12.2%，主要是与第三方购买相比，公司内部销售的眼底相机成本较低。由于公司在收入强劲增长的情况下严格控制费用，2023年公司净亏损缩小至1.33亿元人民币。报告指出，截至2023年鹰瞳科技已与5,671个活跃服务网点建立合作，同比增长...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2424032651?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-02 11:53","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2424032651","market":"hk","top_or_hot":-1,"title":"中信里昂上调鹰瞳科技（2251.HK）目标价至20.7港元，维持买入评级","media":"权证网","content":"<div>\n<p>中信里昂发布研报称，受益于疫情后健康体检活动恢复检测次数增加和平均单价的提升，鹰瞳科技2023年度营收达到2.04亿元人民币，同比增长79.5%。毛利率同比增长12.2%，主要是与第三方购买相比，公司内部销售的眼底相机成本较低。由于公司在收入强劲增长的情况下严格控制费用，2023年公司净亏损缩小至1.33亿元人民币。报告指出，截至2023年鹰瞳科技已与5,671个活跃服务网点建立合作，同比增长...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040211532187d368b3&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中信里昂上调鹰瞳科技（2251.HK）目标价至20.7港元，维持买入评级</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中信里昂上调鹰瞳科技（2251.HK）目标价至20.7港元，维持买入评级\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-02 11:53 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040211532187d368b3&s=b><strong>权证网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>中信里昂发布研报称，受益于疫情后健康体检活动恢复检测次数增加和平均单价的提升，鹰瞳科技2023年度营收达到2.04亿元人民币，同比增长79.5%。毛利率同比增长12.2%，主要是与第三方购买相比，公司内部销售的眼底相机成本较低。由于公司在收入强劲增长的情况下严格控制费用，2023年公司净亏损缩小至1.33亿元人民币。报告指出，截至2023年鹰瞳科技已与5,671个活跃服务网点建立合作，同比增长...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040211532187d368b3&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02251","symbol_name":"鹰瞳科技-B","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040211532187d368b3&s=b","article_id":"2424032651","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040211532187d368b3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2424032651","pubTimestamp":1712030000,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"中信里昂发布研报称，受益于疫情后健康体检活动恢复检测次数增加和平均单价的提升，鹰瞳科技2023年度营收达到2.04亿元人民币，同比增长79.5%。随着市场对人工智能相关主题的兴趣日益浓厚，该行继续看好鹰瞳科技在中国AI视网膜成像市场中的领导地位，同时考虑到鹰瞳科技在医疗和消费健康领域的广阔商业前景和渠道扩展策略，将公司目标价从17.2港元提升至20.7港元，维持买入评级。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"02251":"鹰瞳科技-B"},"translate_title":"CITIC Lyon raised the target price of Eagle Pupil Technology (2251. HK) to HK $20.7, maintaining the purchase rating","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02251":1},"content_text":"中信里昂发布研报称，受益于疫情后健康体检活动恢复检测次数增加和平均单价的提升，鹰瞳科技2023年度营收达到2.04亿元人民币，同比增长79.5%。毛利率同比增长12.2%，主要是与第三方购买相比，公司内部销售的眼底相机成本较低。由于公司在收入强劲增长的情况下严格控制费用，2023年公司净亏损缩小至1.33亿元人民币。报告指出，截至2023年鹰瞳科技已与5,671个活跃服务网点建立合作，同比增长139.2%，包括来着鹰瞳医疗的1,817家医院和基层医疗卫生机构，来自鹰瞳健康的1,868家保险公司和药房，以及来自鹰瞳眼健康的1,986家眼科中心。预计在2024年获批的Airdoc-AIFUNDUS（2.0）将成为一个关键的催化剂，升级后的产品结合新的适应症能够让鹰瞳科技进一步渗透到医疗服务中心网络中，并提升其诊断服务的平均价格。随着市场对人工智能相关主题的兴趣日益浓厚，该行继续看好鹰瞳科技在中国AI视网膜成像市场中的领导地位，同时考虑到鹰瞳科技在医疗和消费健康领域的广阔商业前景和渠道扩展策略，将公司目标价从17.2港元提升至20.7港元，维持买入评级。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2424032651"}